The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation
Por:
Dekker, AD, Ulgiati, AM, Groen, H, Boxelaar, VA, Sacco, S, Falquero, S, Carfi, A, di Paola, A, Benejam, B, Valldeneu, S, Fopma, R, Oosterik, M, Hermelink, M, Beugelsdijk, G, Schippers, M, Henstra, H, Scholten-Kuiper, M, Willink-Vos, J, de Ruiter, L, Willems, L, Loonstra-de Jong, A, Coppus, AMW, Tollenaere, M, Fortea, J, Onder, G, Rebillat, AS, Van Dam, D, De Deyn, PP
Publicada:
1 ene 2021
Resumen:
Background: People with Down syndrome (DS) are at high risk to develop Alzheimer's disease dementia (AD). Behavioral and psychological symptoms of dementia (BPSD) are common and may also serve as early signals for dementia. However, comprehensive evaluation scales for BPSD, adapted to DS, are lacking. Therefore, we previously developed the BPSD-DS scale to identify behavioral changes between the last six months and pre-existing life-long characteristic behavior.
Objective: To optimize and further study the scale (discriminative ability and reliability) in a large representative DS study population.
Methods: Optimization was based on item irrelevance and clinical experiences obtained in the initial study. Using the shortened and refined BPSD-DS II, informant interviews were conducted to evaluate 524 individuals with DS grouped according to dementia status: no dementia (DS, N=292), questionable dementia (DS + Q, N=119), and clinically diagnosed dementia (DS + AD, N=113).
Results: Comparing item change scores between groups revealed prominent changes in frequency and severity for anxious, sleep-related, irritable, restless/stereotypic, apathetic, depressive, and eating/drinking behavior. For most items, the proportion of individuals displaying an increased frequency was highest in DS + AD, intermediate in DS + Q, and lowest in DS. For various items within sections about anxious, sleep-related, irritable, apathetic, and depressive behaviors, the proportion of individuals showing an increased frequency was already substantial in DS + Q, suggesting that these changes may serve as early signals of AD in DS. Reliability data were promising.
Conclusion: The optimized scale yields largely similar results as obtained with the initial version. Systematically evaluating BPSD in DS may increase understanding of changes among caregivers and (timely) adaptation of care/treatment.
Filiaciones:
Dekker, AD:
Univ Groningen, Univ Med Ctr Groningen, Dept Neurol & Alzheimer Ctr, Groningen, Netherlands
Alliade Care Grp, Dept Practice Oriented Sci Res PWO, Heerenveen, Netherlands
Ulgiati, AM:
Univ Groningen, Univ Med Ctr Groningen, Dept Neurol & Alzheimer Ctr, Groningen, Netherlands
Alliade Care Grp, Dept Practice Oriented Sci Res PWO, Heerenveen, Netherlands
Groen, H:
Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
Boxelaar, VA:
Univ Groningen, Ctr Informat Technol, Groningen, Netherlands
Sacco, S:
Inst Jerome Lejeune, Paris, France
Falquero, S:
Inst Jerome Lejeune, Paris, France
Carfi, A:
Fdn Policlin Univ Gemelli IRCCS, Dept Geriatr, Rome, Italy
di Paola, A:
Fdn Policlin Univ Gemelli IRCCS, Dept Geriatr, Rome, Italy
Benejam, B:
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Valldeneu, S:
Hosp Santa Creu & Sant Pau, Memoty Unit, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Dept Neurol, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Fopma, R:
Alliade Care Grp, Dept Practice Oriented Sci Res PWO, Heerenveen, Netherlands
Oosterik, M:
Aveleijn, Borne, Netherlands
Hermelink, M:
Twentse Zorgcentra, Enschede, Netherlands
Beugelsdijk, G:
Ipse Bruggen, Nieuwveen Nootdorp, Netherlands
Schippers, M:
Ipse Bruggen, Nieuwveen Nootdorp, Netherlands
Henstra, H:
Nieuw Woelwijck, Sappemeer, Netherlands
Scholten-Kuiper, M:
Philadelphia Zorg, Amersfoort, Netherlands
Willink-Vos, J:
Severinus, Veldhoven, Netherlands
de Ruiter, L:
Sherpa, Baarn, Netherlands
Willems, L:
Sprank, Zwolle, Netherlands
Loonstra-de Jong, A:
Vanboeijen, Assen, Netherlands
Coppus, AMW:
Radboud Univ Nijmegen Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands
Dichterbij, Gennep, Netherlands
Tollenaere, M:
Univ Antwerp, Dept Biomed Sci, Lab Neurochem & Behav, Antwerp, Belgium
Univ Antwerp, Inst Born Bunge, Antwerp, Belgium
Hosp Network Antwerp ZNA Middelheim & Hoge Beuken, Dept Neurol & Memory Clin, Antwerp, Belgium
Fortea, J:
Fundacio Catalana Sindrome Down, Barcelona Med Ctr, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Memoty Unit, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Dept Neurol, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
Onder, G:
Ist Super Sanita, Dept Cardiovasc Endocrine Metab Dis & Aging, Rome, Italy
Rebillat, AS:
Inst Jerome Lejeune, Paris, France
Van Dam, D:
Univ Groningen, Univ Med Ctr Groningen, Dept Neurol & Alzheimer Ctr, Groningen, Netherlands
Univ Antwerp, Dept Biomed Sci, Lab Neurochem & Behav, Antwerp, Belgium
Univ Antwerp, Inst Born Bunge, Antwerp, Belgium
De Deyn, PP:
Univ Groningen, Univ Med Ctr Groningen, Dept Neurol & Alzheimer Ctr, Groningen, Netherlands
Univ Antwerp, Dept Biomed Sci, Lab Neurochem & Behav, Antwerp, Belgium
Univ Antwerp, Inst Born Bunge, Antwerp, Belgium
Hosp Network Antwerp ZNA Middelheim & Hoge Beuken, Dept Neurol & Memory Clin, Antwerp, Belgium
Green Published
|